الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Hepatitis C virus (HCV) is a health issue that affects a significant proportion of the global population. HCV infection is a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma. The new generation of oral direct-acting antivirals (DDAs) has transformed the treatment of hepatitis C virus infection, demonstrating both high efficacy and high tolerability, it is extremely effective and safe. Aim: This study aimed to assess quality of life among hepatitis C virus patients undergoing Direct Acting Antivirals. Method: Descriptive research design was utilized, included 150 HCV patients undergoing DDAs at Specialty Medical Hospital, Mansoura International Hospital and Bilqas Central Hospital. Data was collected by using two tools, structured interviewing questionnaire and the chronic -Liver -Disease -Questionnaire. Results: fatigue was the most affected domain in our study, the majority of our subject reported presence of fatigue all of the time. Activity was the followed domain affected. Bodily pain was the most affected symptoms in systemic symptom domains. Having problems with concentration was the most affected symptoms in emotional function domain. Abdominal symptoms and worry were the least affected domains in our subjects. Recommendations: Fatigue and activity were the highly problems that faced our study subject so, assessment and management for fatigue and activity should be done for those patients. Bodily pain was the most affected symptom related to systemic symptoms domains in our subjects so, assessment and management of this symptoms is very essential. Further researches should be done on larger and randomized selected sample to generalize the results. Developing fatigue intervention program for this population. Pain relieving measure program should be done for this population. |